English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduDuke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
Tag: checkpoint inhibitor
Atlantic Health System Physicians Co-Author 5 Studies, Presented at American Association for Cancer Research (AACR) Annual Meeting
Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.
Roswell Park Sees Suggestion of Benefit in First Clinical Trial to Combine Beta-Blocker and Checkpoint Inhibitor
The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive. A team of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to disrupt that dynamic so that cancer treatments can be more effective. Their latest work, published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, suggests that a drug widely prescribed to control blood pressure may improve patients’ response to cancer immunotherapy.
Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.
Study Shows Promise for Non-Small Cell Lung Cancer Patients Who Require New Treatment Options
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System. Early results appear promising in this phase 1/2 clinical trial of ADXS-503 being developed by Advaxis, Inc., a new type of cancer therapy which targets “hotspot” mutations that commonly occur in specific cancer types, both by itself and in combination with immunotherapy Keytruda® (pembrolizumab), which is commonly used to treat this type of lung cancer. Dr. Haigentz and colleagues published early results of this study in conjunction with ASCO 2020, the world’s premier scientific meeting for clinical research in oncology.
Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.
Roswell Park Team Proposes Strategy for Making Pancreatic Tumors Respond to Checkpoint Inhibition
A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology. The findings from a team led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, at Roswell Park Comprehensive Cancer Center and published today in the journal Gut suggest a combination treatment approach that can make some breakthrough immunotherapy drugs effective for more patients with pancreatic cancer.
Roswell Park’s Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute (NCI) to expand a promising immunotherapy platform. Funded through the NCI’s Program Project Grant program, this prestigious five-year grant will fund five clinical trials, all focused on a strategy for making some of the most common immunotherapies work for more cancer patients.
Melanoma Is Killing Fewest Americans in Decades
Advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded for this skin cancer, results of a new study suggest.
Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).